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OBJECTIVES We tested the efficacy of two drug treatments, flecainide (F) and the combination of diltiazem
and propranolol (D/P), administered as a single oral dose for termination of the arrhythmic
episodes.
BACKGROUND Both prophylactic drug therapy and catheter ablation are questionable as first-line treatments
in patients with infrequent and well-tolerated episodes of paroxysmal supraventricular
tachycardia (SVT).
METHODS Among 42 eligible patients (13% of all screened for SVT) with infrequent (#5/year),
well-tolerated and long-lasting episodes, 37 were enrolled and 33 had SVT inducible during
electrophysiological study. In the latter, three treatments (placebo, F, and D/P) were
administered in a random order 5 min after SVT induction on three different days.
RESULTS Conversion to sinus rhythm occurred within 2 h in 52%, 61%, and 94% of patients on
placebo, F and D/P, respectively (p , 0.001). The conversion time was shorter after D/P
(32 6 22 min) than after placebo (77 6 42 min, p , 0.001) or F (74 6 37 min, p , 0.001).
Four patients (1 placebo, 1 D/P, and 2 F) had hypotension and four (3 D/P and 1 F) a sinus
rate ,50 beats/min following SVT interruption. Patients were discharged on a single oral
dose of the most effective drug treatment (F or D/P) at time of acute testing. Twenty-six
patients were discharged on D/P and five on F. During 17 6 12 months follow-up, the
treatment was successful in 81% of D/P patients and in 80% of F patients, as all the
arrhythmic episodes were interrupted out-of-hospital within 2 h. In the remaining patients,
a failure occurred during one or more episodes because of drug ineffectiveness or drug
unavailability. One patient had syncope after D/P ingestion. During follow-up, the
percentage of patients calling for emergency room assistance was significantly reduced as
compared to the year before enrollment (9% vs. 100%, p , 0.0001).
CONCLUSIONS The episodic treatment with oral D/P and F, as assessed during acute testing, appears effective
in the management of selected patients with SVT. This therapeutic strategy minimizes the
need for emergency room admissions during tachycardia recurrences. (J Am Coll Cardiol
2001;37:548–53) © 2001 by the American College of Cardiology
Paroxysmal supraventricular tachycardia (SVT) is com-
monly due to atrioventricular (AV) nodal reentry or AV
reentry secondary to an AV accessory pathway. In patients
with frequent episodes of SVT, long-term oral prophylaxis
with antiarrhythmic drugs treatment has long been used to
prevent clinical recurrences. However, both the daily intake
of antiarrhythmic agents, sometimes in multiple doses or
drug combinations, and the risk of drug-related adverse
effects are recognized disadvantages of long-term prophy-
lactic therapy. In addition, despite optimal drug adminis-
tration and compliance, relapses are not infrequent in these
patients (1).
Recently, radiofrequency catheter ablation has been in-
troduced in clinical practice and proven to be a highly
effective curative therapy for SVT. However, major compli-
cations have been reported in up to 3% of patients under-
going this therapy (2); this finding suggests that catheter
ablation should be primarily recommended in those patients
in whom paroxysmal SVTs indeed produce a detrimental
impact on their life quality.
Not infrequently, patients with SVT may present with
episodes that are rare and well-tolerated but long enough to
require emergency room admission. In these patients, long-
term oral prophylaxis or cateter ablation may not represent
the most appropriate first-line treatment. Rather, an opti-
mal approach in this group of patients might be an “episodic
treatment” consisting of a single-dose oral ingestion of an
antiarrhythmic drug at the time and site of arrhythmia onset
(3,4). This type of treatment has already been investigated
in patients with paroxysmal atrial fibrillation (5–8), but not
yet in patients with paroxysmal SVT, except for subgroups
with frequent episodes (9–11).
The aims of this study were to verify: 1) the efficacy of
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antiarrhythmic drugs as an acute oral dose to terminate SVT
in patients with infrequent, long-lasting and well-tolerated
episodes of this tachycardia, and 2) verify the out-of-
hospital feasibility and safety of this treatment. To this
purpose, we have utilized in a controlled design oral
flecainide (F) and oral diltiazem plus propranolol (D/P).
These drugs were chosen because of the encouraging results
reported in the literature (10,11).
METHODS
Inclusion criteria were as follows: 1) age between 18 and 75
years; 2) infrequent (#5/year), well-tolerated episodes of
electrocardiographycally documented paroxysmal SVT
prompting for treatment in an emergency room at least once
each year; 3) electrocardiogram (ECG) during tachycardia
suggestive of AV nodal or AV reentrant tachycardia (12,13).
The SVT episodes were defined as well-tolerated if they
were not associated with severe symptoms, including dys-
pnea, presyncope or syncope, and did not prevent normal
activities, such as walking and driving.
Patients were excluded if they had one or more of the
following findings: ventricular preexcitation; ischemic heart
disease; resting sinus rate ,50 beats/min; left ventricular
dysfunction (i.e., ejection fraction ,50% and/or history of
heart failure); very severe general diseases; recent myocardial
infarction or stroke or other acute diseases; a need for
long-term treatment with beta-blockers, calcium antago-
nists, digitalis or other antiarrhythmic drugs; a history of
documented sustained atrial or ventricular tachyarrhyth-
mias.
The study protocol was approved by the ethic committees
of the two recruiting institutions (Ospedale Civile, Cento,
and Arcispedale S. Maria Nuova, Reggio Emilia, Italy) and
patients were required to give written informed consent.
All patients underwent clinical, chest X-ray and two-
dimensional echocardiographic examination. Other diag-
nostic investigations, such as exercise stress testing, were
performed only when clinically indicated.
Electrophysiologic study. All patients in a nonsedated
state underwent an electrophysiologic study according to
standard techniques. A single quadripolar catheter was
percutaneously introduced into the right femoral vein and
advanced to the right atrium, where a programmed electrical
stimulation consisting of incremental pacing and extra-
stimulus testing (S1, S2, S3) was performed. If the clinical
SVT was not induced, the catheter was advanced into the
right ventricular apex and programmed stimulation re-
peated. After induction of SVT, the catheter was moved to
the His bundle area, the coronary sinus, or other areas to
enable accurate identification of the type of tachycardia. If
the SVT was an AV nodal or AV reentrant tachycardia
(14,15), the patient was enrolled and underwent each of the
following three treatments: 1) placebo, 2) single oral dose of
F (about 3 mg/kg), and 3) single oral dose combination of
120 mg D and 80 mg P. The three treatments were
investigated on three consecutive days according to a ran-
dom order. The catheter was left in situ for three days. A
distinct computer-generated randomization sequence was
used by each center. To enable a more rapid absorption,
tablets were crushed and administered with sugar. All drugs
were administered 5 min after induction of stable SVT, and
the time-to-SVT termination was carefully monitored.
Electrical termination of SVT was attempted if no sponta-
neous conversion to sinus rhythm had occurred within 2 h
from drug administration or arrhythmia-related severe
symptoms were observed erlier on and treatment was
considered ineffective. Blood pressure and heart rate were
taken before the induction of SVT, 1 min after induction,
every 10 min during tachycardia, and 1 and 15 min after
tachycardia interruption. If SVT was noninducible or lasted
,5 min during one of the three electropharmacological
studies, the patient was excluded from analysis because it
was not possible to evaluate and compare the efficacy of the
treatments.
Follow-up. Patients were discharged on the most effective
treatment (showing the shortest conversion time; F or D/P).
If this treatment had induced severe adverse effects, includ-
ing symptomatic arterial hypotension, systolic blood pres-
sure lower than 80 mm Hg, sinus bradycardia less than 50
beats/min and 2nd or 3rd degree AV block, the other
treatment was prescribed. Patients in whom none of the two
active drug treatments had proven effective were referred for
catheter ablation of the clinical arrhythmia.
Before discharge, all patients were instructed to crush
their tablet and to swallow it 5 min after the onset of the
clinical arrhythmia. Patients were also requested to carefully
report in an appropriate form the number of arrhythmia
episodes, whether the drug was effective in interrupting
them, the time duration between drug intake and termina-
tion of symptoms and the adverse effects. Finally, patients
were advised not to take more than one oral dose during a
24-h period and to refer to an emergency room if the
arrhythmia had not terminated whithin 2 h from drug
ingestion. After discharge, patients were followed in the
outpatient clinic every four months.
Statistical analysis. The data were analyzed using the
chi-square or Fisher exact test, analysis of variance with or
without Benferroni correction, and paired Student t test, as
appropriate. Significance was established at p , 0.05.
Results were given as mean 6 standard deviation.
Abbreviations and Acronyms
AV 5 atrioventricular
D/P 5 diltiazem and propranolol
ECG 5 electrocardiogram
F 5 flecainide
SVT 5 supraventricular tachycardia
549JACC Vol. 37, No. 2, 2001 Alboni et al.
February 2001:548–53 Treatment of Supraventricular Tachycardia
RESULTS
The trial profile and the results of acute testing are reported
in Figure 1. Out of 320 patients referred between March
1995 and June 1998 for treatment of SVT (12,13), 42
patients (13%) met the eligibility criteria. Of these, 37 (16
men; 47 6 11 years; range 25 to 75 years) gave written
informed consent and were enrolled in the study. Two
patients had hypertensive cardiovascular disease, whereas no
signs of underlying heart disease were found in the remain-
ing 35. In the year preceding hospital admission, the
frequency of SVT episodes per patient had been 3.6 6 1.3
and the number of emergency room admissions per patient
1.8 6 0.8. Twenty-one patients (58%) had been or still were
under oral antiarrhythmic prophylaxis prior to hospital
admission.
Electrophysiologic study. In 33 patients, a regular SVT
was inducible at time of electrophysiologic study: AV nodal
reentrant tachycardia in 25 (76%) and orthodromic AV
reentrant tachycardia in 8 (24%) patients. In all cases,
during electrophysiologic study the 12-lead ECG of the
induced tachycardia mached the 12-lead ECG morphology
of the spontaneous arrhythmia. In four patients (11%) SVT
was noninducible or lasted ,5 min; these patients were
excluded from analysis and referred for catheter ablation. Of
the 33 patients with inducible SVT, conversion to sinus
rhythm without pacing was achieved within 2 h in 17 (52%)
after placebo, in 20 (61%) after F, and in 31 (94%) patients
after D/P (p , 0.001).
Adverse effects. Hypotension after drug administration
requiring electrical termination of SVT appeared in four
patients: in one after placebo, in two after F and in one
patient after D/P. Sinus bradycardia (heart rate ,50 beats/
min) following SVT interruption was observed in four
patients: in one after F and in three after D/P. Minor side
Figure 1. Trial profile. AV 5 atrioventricular; SVT 5 supraventricular tachycardia.
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effects (nausea, cephalea, sweating) were observed in four
patients after placebo, in five after F and in three after D/P.
No patient showed 2nd or 3rd degree AV block following
SVT termination.
Conversion time. The conversion time to sinus rhythm
was evaluable in 32 patients after placebo, in 31 after F and
in 32 after D/P. It was shorter after D/P (32 6 22 min) than
it was after placebo (77 6 42 min, p , 0.001) or F (74 6
37 min, p , 0.001). The conversion time after F did not
significantly differ from that after placebo. The treatment
associated with the shortest conversion time was placebo in
6 patients (20%), F in 2 (8%), and D/P in 21 (72%). The
D/P was more effective than placebo (p , 0.001) and F
(p , 0.001), whereas the efficacy of F did not significantly
differ from that of placebo.
Follow-up. Of the 33 patients with inducible SVT, 2 were
referred for catheter ablation because, according to the study
design, both drugs (F and D/P) were ineffective or had
induced severe adverse effects. Of the remaining 31 patients,
26 were discharged on D/P and 5 on F; the choice was
based on acute efficacy results. During 17 6 12 months’
follow-up (range, 4 to 48 months), 140 episodes of the
clinical arrhythmia were reported, 115 (4.4 per patient)
occurring in patients assigned to D/P and 25 (5.0 per
patient) in patients assigned to F. Twenty-three episodes
were self-terminating within 5 min from the onset and,
therefore, they have not been treated, according to the study
design.
Of the 26 D/P patients, the treatment was successful in
21 (81%) as all the arrhythmic episodes were interrupted
out-of-hospital within 2 h. In the remaining five patients, at
least one episode lasted more than 2 h because of ineffec-
tiveness of the treatment in three (11%) and of drug
unavailability in two (8%) patients. These five patients
reported treatment failure during nine arrhythmic episodes.
The conversion time of the treated episodes was 41 6
24 min and was similar to that observed during acute
testing. Three patients (11%) called for emergency room
assistance for SVT termination.
Of the five F patients, the treatment was successful in
four (80%) and in the remaining patient the drug was
unavailable during one arrhythmic episode, and this lasted
more than 2 h. The conversion time of the treated episodes
was 43 6 18 min. No patient called for emergency room
assistance.
A failure of the out-of-hospital treatment occurred dur-
ing one or more episodes in 6 of the 31 patients (19%, 95%
CI, 1 5%, 1 33%) because of drug ineffectiveness or drug
unavailability.
During follow-up, the percentage of patients calling for
emergency room assistance was significantly reduced as
compared to the year before enrollment (3/31 [9%] vs.
31/31 [100%], p , 0.0001).
Adverse effects during one or more arrhythmic episodes
were reported in 11 patients: in 10 patients after D/P
(asthenia lasting several hours in 6 patients, nausea in 1,
vomiting in 1, cephalea in 1, and syncope with trauma in 1)
and in 1 patient after F (vomiting).
In seven patients (27%), the episodic treatment was
discontinued after 13 6 6 months follow-up: in one patient
because of syncope with trauma, in one because of concom-
itant atrial fibrillation requiring long-term prophylactic
antiarrhythmic treatment, and in five patients because the
arrhythmic episodes became more frequent and the patients
underwent catheter ablation. At the end of follow-up, 24
patients (73%) were satisfied with the treatment and were
advised to continue with it.
DISCUSSION
Main finding of the study. The main finding of the
present study was that a single-dose of self-administered
D/P or F at the time of arrhythmia onset appears an
effective treatment of patients with infrequent, long-lasting
and well-tolerated SVTs. Selection of drug treatment was
based on the acute drug efficacy in terminating electrically
induced SVT in the individual patient. This therapeutic
strategy proved highly effective to minimize the need for
emergency room admission during the SVT recurrences and
was associated with a low incidence of severe adverse events.
Selection of patients and therapeutic strategy. The prev-
alence, among patients with paroxysmal SVT, of those with
infrequent and well-tolerated episodes, though long enough
to call for emergency room assistance, is not known. In the
present study, these patients accounted for 13% of all
patients referred for treatment of SVT during the enroll-
ment period, thus representing a small group. The remain-
ing patients reported more frequent episodes and/or severe
symptoms and/or short, self-terminating episodes. Single-
dose oral ingestion of an antiarrhythmic drug for termina-
tion of arrhythmia is an appealing form of treatment for
rarely symptomatic patients (16) because it prevents the
disadvantages of long-term oral prophylaxis (1) and the
potential complications associated with catheter ablation (2).
Although other drugs had also been investigated (9), D/P
and F were selected for evaluation in this study because they
appeared to be effective in patients with frequent SVT
(10,11). The mode of action of single-dose oral ingestion of
D/P and F has been previously investigated (10,11). When
both tablets are crushed into powder form, oral D/P is
readily absorbed and high serum levels are achieved within
30 min (11).
In a study by Yeh et al. (11), administration of a single
oral dose (D 120 mg; P 160 mg) of this combination was
associated with termination within 3 h of drug intake of
electrically induced SVT in 14 (93%) out of 15 cases. Of
note, at the dosage administered by the investigators, two
patients (13%) developed 2nd degree AV block after SVT
interruption. In the Yeh et al. (11) study, 50 out of 51 SVT
episodes occurring during 5 6 1 months follow-up were
converted within 3 h (conversion time, 21 6 16 min) after
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a single D/P oral dose; no major drug-related adverse effects
were reported.
In another study by Musto et al. (10), the efficacy of a
single oral dose of F (about 3 mg/kg) to terminate electri-
cally induced SVT in 25 children and young adults was
tested using a noncontrolled design. Although this therapy
was associated with SVT termination within 3 h of drug
intake in 22 patients (88%) (conversion time, 80 6 34 min),
the true efficacy of F could not be assessed in the absence of
a placebo arm.
Efficacy of drug treatment at time of acute testing. In the
present study, we chose to select the antiarrhythmic drug
based on its efficacy to terminate electrically induced SVT in
the individual patient. Because of the risk of induction of
2nd degree AV block, as reported by Yeh et al. (11), a dose
of 80 mg rather than 160 mg P was used in combination
with D. Also, for a successful single-dose drug treatment
during the electrically induced SVT, we arbitrarily selected
a time limit of 2 h rather than 3 h, as previously reported
(10,11). This decision was based on a more conservative
approach for assessment of drug efficacy in the clinical
setting before calling for emergency room assistance.
During the acute testing, the true drug efficacy was
investigated by comparing the time of SVT conversion into
sinus rhythm of the two drug treatments with that of
placebo. In general, D/P, but not F, proved effective to
shorten the conversion time compared to placebo.
Efficacy of drug treatment during follow-up. Selection of
drug therapy based on the results of acute testing was
associated with a satisfactory clinical outcome during the
follow-up. In fact, oral D/P interrupted within 2 h all
out-of-hospital arrhythmic episodes in 81% of the patients
and oral F in 80%; in the remaining patients, a failure
occurred during one or more episodes because of drug
ineffectiveness or drug unavailability.
A remarkable impact of the proposed treatment strategy
was the dramatic reduction in emergency room admissions
for medical care. These data are of clinical significance,
because emergency room admission often represents the
most important concern for these patients.
A not unexpected finding was that the clinical course of
these patients may deteriorate with time. This was the case
in five patients (16%) of this study, in whom the occurrence
of more frequent episodes required discontinuation of the
investigated therapeutic strategy after 13 6 6 months
follow-up; all five patients were referred for catheter abla-
tion.
Drug-related adverse effects. During follow-up, one pa-
tient had syncope with trauma 15 min after D/P ingestion,
and drug treatment was discontinued. Although paroxysmal
SVT may cause syncope (17,18), no previous such episodes
were reported in this patient population. Therefore, it is
likely that this symptom represents a true drug-related
adverse effect. Although rarely reported, the possibility of
syncope should prompt physicians to recommend the pa-
tient at least to take a sitting position when using a
self-administered single-dose oral treatment. Given the
administration modality, minor drug-related adverse effects
were accepted by patients in comparison with the associated
clinical benefit.
Clinical implications. Although useful to identify the
most effective drug treatment on an individual basis, the
strategy introduced here appears of questionable practica-
bility in daily clinical routine. Given its documented supe-
riority to placebo and F, D/P could reasonably be tested as
a first-choice treatment during a single electropharmaco-
logical study. Based on the data from the present study, an
acute success rate of about 70% would be expected (consid-
ering the possibily of SVT noninducibility and of severe side
effects). Treatment of nonresponders remains to be investi-
gated, and, at this time, may include testing of alternative
drugs as well as other forms of therapy. Because the episodic
treatment with D/P was not tested in patients with ventric-
ular preexcitation, sinus bradycardia and left ventricular
dysfunction, the therapeutic strategy used in the present
study cannot be proposed in these patient categories.
Study limitations. Owing to the study design, we cannot
exclude that some potentially eligible patients with SVT
were excluded because of an inaccurate diagnosis of the
clinical arrhythmia on 12-lead ECG.
In about 10% of the patients with infrequent episodes of
paroxysmal SVT, tachycardia is noninducible during elec-
trophysiological study or lasts ,5 min; therefore, in these
patients it is not possible to test an episodic treatment.
During follow-up, arrhythmic episodes and concomitant
drug treatment were assessed based on patient symptoms.
We cannot exclude that some of these episodes were
secondary to arrhythmias other than SVT (i.e., atrial fibril-
lation, atrial tachycardia, etc.). However, the efficacy of the
tested therapeutic strategy was investigated with a clinical
rather than an electrophysiological purpose, and the re-
ported rates of success appear clinically valuable, regardless
of the specific arrhythmia associated with the patient symp-
toms.
During the follow-up period, the time between drug
intake and tachycaria termination was measured by the
patient and, therefore, it cannot be considered very precise.
Selection of out-of-hospital drug treatment was based on
its acute efficacy on electrically induced SVT. Although it
was associated with a low incidence of patients calling for
emergency room assistance during follow-up, this method is
invasive and requires multiple electropharmacological stud-
ies. A more practical approach would be an empiric one.
Whether an empiric approach could result in a clinical
efficacy similar to that of the mode introduced in the present
study remains to be investigated.
Finally, in the absence of a randomized controlled design
for out-of-hospital management of arrhythmic episodes, it
is not possible to ascertain conclusively whether the favor-
able impact on clinical outcome of the tested strategy is
inherently related to the drug efficacy or to the strategy
itself.
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CONCLUSIONS
Data from the present study show that episodic treatment
with oral D/P and F, as assessed on an individual basis at
time of acute testing, appears effective in about 70% of
patients with infrequent and well-tolerated episodes of AV
nodal reentrant tachycardia or orthodromic AV reentrant
tachycardia. The incidence of severe adverse events appears
low; however, safety will have to be evaluated in a larger
group of patients. Using this method, D/P appears an
interesting therapeutic approach in these patients; in par-
ticular, this therapeutic strategy minimizes the need for
emergency room admission during the acute event. Before
being prescribed, D/P must be tested in hospital for
assessment of efficacy and safety during a single electro-
pharmacological study or during a spontaneous SVT attack.
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